1. Redondo-Lopez V, Cook RL, Sobel JD. Emerging role of lactobacilli in the control and maintance of the vaginal bacterial microflora. Rev Infect Dis, 1990; 164(1): 94-100.
2. Osset J, Bartolome RM, et al. Assessment of the capacity of Lactobacillus to inhibit the growth of uropathogens and block their adhesion to vaginal epithelial cells. J Infect Dis, 2011; 183(3): 485-491.
3. Döderlein A. Das scheidensekret und seine bedeutung fur puerperalfieber. Zentbl Bakteriol Hyg Abt, 1892; 11: 699.
4. Thomas S. Doderlein`s bacillus: Lactobacillus acidophilus. J Infect Dis, 1928; 43: 218-227.
5. Lauer E, Helming C, Kandler O. Heterogeneity of the species Lactobacillus acidophilus (Moro) Hansen and Mosqout as revealed by biochemical characteristics and DNA - DNA hybridization. Zentbl Bakteriol Microbiol Hyg Abt, 1980; 1: 150-168.
6. Verhelst R, et al. Comparision between Gram stain and cultures for the characterization of vaginal microflora: definition og a distinct grade that resembles grade I microflora and revised categorization of grade I microflora. BMC Microbiol, 2005: 5: 61.
7. Antonio MA, Hawes SE, Hillier SL. The identification of vaginal Lactobacillus species and the demographic and microbiologic characteristics of women colonized by these species. J Infec Dis, 1990; 180: 1950-1956.
8. Rabe LK, Hillier SL. Optimization of media for detection of hydrogen peroxide by Lactobacillus species. J Clin Microbiol, 2003; 41: 3260-3264.
9. Wilks M, Wiggins R, et al. Identification and H2O2 productions of vaginal Lactobacilli from pregnant women at high risk of preterm birth and relation with outcome. J Clin Microbiol, 2003; 42: 713-717.
10. Anukam KC, Osazuwa EO, et al. Lactobacillus vaginal microbiota of women attending a repoductive health care service in Benin city, Nigeria. Sex Transm Dis, 2006; 33: 59-62.
11. Ahrne S, Nobaek S, et al. The norma; Lactobacillus flora on heakth human rectal and oral mucosa. J Appl Microbiol, 1998; 85: 88-94.
12. Benno Y, Endo K, et al. Comparision of fecal microflora of elderly persons in rural and urban areas of Japan. Appl Environ Microbiol, 1989; 55: 1100-1105.
13. Zhou X, Bent SJ, et al. Characterization of vaginal microbial communities in adult healthy women using cultivation-independent methods. Microbiology, 2004; 150: 2565-2573.
14. Hymen RW, Fukushima M, Diamond L. Microbes on the human vaginal epithelium. Proc Natl Acad Sci USA, 2005; 102: 7952-7957.
15. Ravel J, et al. Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci USA, 2011; 108(1): 4680-4687.
16. Srinivasan S, Liu C, et al. Temporal variability of human vaginal bacteria and relationship with bacterial vaginosis. PloS ONE, 2010; 5:e10197.
17. Zhou X, Brotman RM, et al. Recent advances in understanding the microbiolgy of the female reproductive tract and the causes of preterm birth. Infect Dis Ob Gyn, doi: 10.1155/2010/737425.
18. Lamont RF, Sobel JD, et al. The vaginal microbiome: new information about genital tract flora using molecular based techniques. BJOG, 2011; 118: 533-549.
19. Gardner HL, Dukes CD. Haemophilus vaginalis vaginitis. A newly defined specific infection previously classified “Nonspecific” vaginitis. Am J Obstet Gynec, 1995; 69: 962-976.
20. Hill GB. The microbiology of bacterial vaginosis. Am J Obstet Gynec, 1993; 169: 450-454.
21. Amsel R, Totten PA, Spegielb CA. Nonspecificvaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Obstet Gynec, 1983; 74: 14-22.
22. Ferris MJ, Masztal A, et al. Association of Atopobium vaginae, a recently described metronidazole resistant anaerobe, with bacterial vaginosis. BMC Infect Dis, 2004; 4: 5.
23. Menard JP, Fenollar F, et al. Molecular quantification of Gardnerellavaginalis and Atopobiumvaginae loads to predict bacterial vaginosis. Clin Infect Dis, 2008; 47: 33-43.
24. Svidsinski A, Mending W, et al. Adherent biofilms in bacterial vaginosis. Obstet Gynecol, 2005; 106: 1013-1023.
25. Fredricks DN, Fiedler TL, Marrazzo JM. Molecular identification of bacteria associated with bacterial vaginosis. N Engl J Med, 2005; 353: 1899-1911.
26. Wertz J, Isaacs-Cosgrove N, et al. Temporal shifts in microbial communities in nonpregnant African-American women with and without bacterial vaginosis. Interdiscip Perspect Infect Dis, 2008:181-253.
27. Gardner HL. Desquamative inflammatory vaginitis: a newly defined entity. Am J Obstet Gynec, 1968; 102: 1102-1105.
28. Sobel JD. Desquamative inflammatory vaginitis: a new subgroup of purulent vaginitis responsive to topical 2% clindamycin therapy. Am J Obstet Gynec, 1994; 171: 1215-1220.
29. Donders GGG, Vereecken A, et al. Aerobic vagintis: abnormal vaginal flora entity that is distinct from bacterial vaginosis. Br J Obstet Gynecol, 2002; 109: 1-10.
30. Ralph SG, Rutherford AJ, Wilson JD. Influence of bacterial vaginosis on conception and miscarriage in the first trimester: a cohort study. BMJ, 1999: 220-223.
31. Hay PE, Lamont RF, et al. Abnormal bacterial colonisation of the genital tract and subsequent preterm delivery and late miscarriage. BMJ, 1994; 308(6924): 295-298.
32. Llahy-Camp JM, et al. Association of bacterial vaginosis with the history of second trimester miscarriage. Hum Reprod, 1996; 11: 1575-1578.
33. Larsson PG, Fahraeus L, et al. Predisposing factors for bacterial vaginosis, treatment efficacy and pregnancy outcome among term deliveries; results from a preterm delivery study. BMC Womens Health, 2007; 7: 20.
34. Leitich H, Kiss H. Asymptomatic bacterial vaginosis and intermediate flora as risk factors for adverse pregnancy outcome. Best Pract Res Clin Obstet Gynaecol, 2007; 21(3): 375-390.
35. Donders GG, Spitz B, et al. The ecology of the vaginal flora at first prenatal visit is associated with preterm delivery and low birth weight. Open Infect Dis J, 2008; 2: 45-51.
36. Subramaniam A, Abramovici A, et al. Antimicrobials for preterm birth prevention: an overview. Doi: 10/2012/157159
37. Hack M, Fanaroff AA. Outcomes of children of extremely low birthweight and gestational age in the 1990s. Semin Neonat, 2000; 5(2): 89-106.
38. Goldenberg RL, Hauth JC, Andrews WW. Intrauterine infection and preterm delivery. NEJM, 2000; 342(20): 1500-1507.
39. Rezeberga D, Lazdane G, et al. Placental histological inflammation and reproductive tract infections in a low risk pregnant population in Latvia. Acta Obstet Gynecol Scand, 2008; 87(3): 360-365.
40. Romero R, Chaiworapongsa T, et al. Bacterial vaginosis, the inflammatory response and the risk of preterm birth: a role for genetic epidemiology in the prevention of preterm birth. Am J Obstet Gyn, 2004; 190(6): 1509-1519.
41. Mc Donald HM, Brocklehurst P, Gordon A. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database of Systematic reviews, 2007; doi 10.1002/14651858.
42. Ugwumadu A, Reid F, et al. Natural history of bacterial vaginosis and intermediate flora in pregnancy and effect of oral clindamycin. ObstetGynecol, 2004; 104: 114-119.
43. Soper DE, Bump RC, Hurt WG. Bacterial vaginosis and trichomoniasis vaginitis are risk factors for cuff cellulitis after abdominal hysterectomy. Am J Obstet Gynecol, 1990; 163: 1016-1021.
44. Cu-Uvin S, Hogan JW, et al. Prevalence of lower genital tract infections among human immunodefiency virus (HIV) - seropositive and high-risk HIV-Seronegative women. HIV Epidemilogy Research Study Group. Clin Infect Dis, 1999; 29: 1145-1150.
45. Plitt SS, Garfein RS, et al. Prevalence and correlates of Chlamydia trachomatis, Neisseria gonorrhoeae, Trichamonas vaginalis infections, and bacterial vaginosis among cohort of young injection drug users in Baltimore. Sex Transm Dis, 2005; 32: 446-453.
46. Verstraelen H, Verhelst R. Bacterial vaginosis: an update on diagnosis and treatment. Expert Rev Anti Infect Ther, 2009; 7(9): 1109-1124.
47. Austin MN, Beigi RH, et al. Microbiological response to treatment of bacterial vaginosis with topical clindamycin or metronidazole. J Clin Microbiol, 2005; 43(9): 4492-4497.
48. Baltimore RS. Consequences of prophylaxis for group B streptococcal infections of the neonate. Semin Perinatol, 2007; 31(1): 33-38.
49. Schwebke JR, Desmond R. A randomised trial of the duration of therpay with metronidazole plus ao minus azithromycin for treatment of symptomatic bacterial vaginosis. Clin Infect Dis, 2007; 44: 213-219.
50. Lamont RF, Duncan SH, et al. Intravaginal clindamycin to reduce preterm birth in women with abnormal vaginal genital tract flora. Obstet Gyn, 2003; 101: 516-522.
51. Kurkinen-Raty S, Vuopala M, et al. A randomised contolled trial of vaginal clindamycin for early pregnancy bacterial vaginosis. BJOG, 2000; 107(11): 1427-1432.
52. Ledger WJ, Witkin SS. Vulvovaginal infections. London, UK: Manson Publishing Ltd; 2010: 52.
53. Bradshaw CS, Tabrizi SN, et al. The association of Atopobium vaginae and Gardnerella vaginalis with bacterial vaginosis and recurrence after oral metronidazole therapy. J Infect Dis, 2006; 194: 828-836.
54. Svidsinski A, Mending W, et al. An adherent Gardnerella vaginalis biofilm persists on the vaginal epithelium after standart therapy with oral matronidazole. Am J Obstet Gynecol, 2008; 198: 97-106.
55. Sobel JD, Ferris D, et al. Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterail vaginosis. Am J Obstet Gynecol, 2006; 194: 1283-1289.
56. Andreu A. Lactobacillus as probiotic for preventing urogenital infections. Rev Med Microbiol, 2004; 15: 1-6.
57. Reid G, Bocking A. The potential for probiotics to prevent bacterial vaginosis and preterm labor. Am J Obstet Gynec, 2003; 189(4): 1202-1208.
58. Mastromarino P, Brigidi P, et al. Characterization and selection of vaginal Lactobacillus strains for the preparation of vaginal tablets. J Appl Microbiol, 2002; 93: 884-893.
59. Boris S, Suarez JE, et al. Adherence of human vaginal lactobacilli to vaginal epithelial cells and interaction with uropathogens. Infect Immun, 1998; 66: 1985-1989.
60. Hallen A, Jarstrand C, Pahlson C. Treatment of bacterial vaginosis with lactobacilli. Sex Transm Dis 1992; 19: 146-148.
61. Ozkinay E, Terek MC, et al. The effectiveness of live lactobacilli in combination with low dose oestriol (Gynoflor) to restore the vaginal flora after treatment of vaginal infections. Int J ObstetGynecol, 2005; 112: 234-240.
62. Eriksson K, Carlsson B, et al. A double-blind treatment study of bacterial vaginosis with normal vaginal lactobacilli after an open treatment with vaginal clindamycin ovules. Acta Derm Venereol, 2005; 85: 42-46.
63. Reid G, Burton J, et al. Nucleic acid-based diagnosis of bacterial vaginosis and improved management using probiotic lactobacilli. J Med Food, 2004; 7: 223-228.
64. Falagas ME, Betsi GI, Athanasiou S. Probiotics for the treatment of women with bacterial vaginosis. ClinMicrobiol Infect, 2007; 13: 657-664.
65. Othman M, Neilson JP, Alfirevic Z. Probiotics for preventing preterm labour. Cochrane Database of Systematic reviews. DOI: 10.1002/14651858
66. Holley RL, Richter HE, et al. A randomized, doule-blind clinical trial of vaginal acidification versus placebo for the treatment of symptomatic bacterial vaginosis. Sex Transm Dis, 2004; 31: 236-238.
67. Boeke AJ, Dekker JH, et al. Effect of lactic acid suppositories compared with oral metronidazole and placebo in bacterial vaginosis: a randomised clinical trial. Genitourin Med, 1993; 69: 388-392.
68. Fiorilli A, Molteni B, Milani M. Successful treatment of bacterial vaginosis with a polycarbophil-Carbopol acidic vaginal gel: results from a randomised double-blind, placebo-controlled trial. Eur J Obstet Gynecol Reprod Biol, 2005; 120(2): 202-205.
69. Polatti F, Rampino M, et al. Vaginal pH-loweing effect of locally applies vitamin C in subjects with high vaginal pH. Gynecol Endocrinol, 2006; 22(4): 230-234.
70. Petersen EE, Magnani P. Efficacy and safety of Vitamin C vaginal tablets in the treatment of non-specific vaginitis. A randomized, double-blind, placebo-controlled study. Obst & Gynec, 2004; 117: 70-75.
71. Petersen EE, Genet M, et al. Efficacy of vitamin C vaginal tablets in the treatment of bacterial vaginosis: a randomized, double-blind, placebo-controlled clinical trial. Arzneimittelforschung, 2011; 61(4): 260-265.